Piper plays down significance of Tesla Autopilot case in Florida
In recent transactions involving Seres Therapeutics, Inc. (NASDAQ:MCRB), Teresa L. Young, the Executive Vice President, Chief Commercial & Strategy Officer, sold 3,338 shares of common stock. These shares were sold on February 18, 2025, at a weighted average price of approximately $0.8102 per share, amounting to a total value of $2,704.
The sales were conducted under a Rule 10b5-1 plan, which was established to cover taxes related to the vesting of restricted stock units. Following these transactions, Young retains direct ownership of 97,536 shares of Seres Therapeutics common stock. According to InvestingPro analysis, the company faces challenges with cash burn and volatile stock price movements. InvestingPro subscribers have access to 8 additional key insights about MCRB’s financial health and market position.
Additionally, on February 15, 2025, Young acquired 10,470 shares of common stock through the vesting of restricted stock units. These acquisitions were executed at no cost, reflecting the conversion of previously held restricted stock units. The company’s EBITDA stands at -$36.4 million for the last twelve months, with a current ratio of 1.12.
In other recent news, Seres Therapeutics has received a $50 million installment payment from Nestlé Health Science as part of the transition obligations following the sale of Seres’ VOWST business. The company expects an additional $25 million payment in July 2025, which will support its operations into early 2026. The FDA has granted Breakthrough Therapy designation to Seres’ investigational drug SER-155, aimed at reducing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant. This designation follows positive Phase 1b study results showing a 77% reduction in bacterial bloodstream infections compared to placebo. In a strategic move, Seres Therapeutics appointed Dr. Hans-Juergen Woerle as a new director to its Board, expanding it to nine members. This appointment was part of a rights agreement with Nestlé, who owns a significant stake in the company. Dr. Woerle brings extensive experience from his previous roles at Nestlé Health Science and other biotechnology firms. These developments underscore Seres Therapeutics’ ongoing efforts to strengthen its leadership and advance its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.